Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled)

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Currently amended) A method for improving ~~treating a disorder of perception, concentration,~~ learning and/or memory , comprising administering to a mammal ~~in need of such treatment~~ an effective amount of a selective PDE 2 inhibitor which inhibits

human PDE 2 more strongly than it inhibits the human cAMP PDEs 3B, 4B and 7B, and which has the general formula (I)



(I)

wherein

A=D represents N=N, N=CH or CR^5=N, in which R^5 denotes hydrogen, methyl, ethyl or methoxy,

R^1 and R^2 represent, together with the adjacent carbon atom, hydroxymethylene or carbonyl, and

R^3 and R^4 represent independently of one another methyl, ethyl, methoxy, ethoxy or a radical of the formula $SO_2NR^6R^7$,

in which

R^6 and R^7 denote, independently of one another, hydrogen, C_1-C_6-alkyl, C_3-C_7-cycloalkyl, or

R^6 and R^7 form, together with the adjacent nitrogen atom, an azetidine-1-yl, pyrrol-1-yl, piperid-1-yl, azepin-1-yl, 4-methylpiperazin-1-yl or morpholin-1-yl radical,

or a pharmaceutically acceptable salt thereof.

11. (Cancelled)

12. (Cancelled)

13. (Currently amended) A method for treating a disorder of perception, concentration, learning and/or memory, ~~The method of claim 10,~~ where said disorder of perception,

concentration, learning and/or memory is a result of stroke or Alzheimer's disease [[.]] _, comprising administering to a mammal in need of such treatment an effective amount of a selective PDE 2 inhibitor which inhibits human PDE 2 more strongly than it inhibits the human cAMP PDEs 3B, 4B and 7B, and which has the general formula (I)



(I)

wherein

A=D represents N=N, N=CH or CR^5=N, in which R^5 denotes hydrogen, methyl, ethyl or methoxy,

R^1 and R^2 represent, together with the adjacent carbon atom, hydroxymethylene or carbonyl, and

R^3 and R^4 represent independently of one another methyl, ethyl, methoxy, ethoxy or a radical of the formula $SO_2NR^6R^7$,

in which

R^6 and R^7 denote, independently of one another, hydrogen, C_1-C_6-alkyl, C_3-C_7-cycloalkyl, or

R^6 and R^7 form, together with the adjacent nitrogen atom, an azetidine-1-yl, pyrrol-1-yl, piperid-1-yl, azepin-1-yl, 4-methylpiperazin-1-yl or morpholin-1-yl radical,

or a pharmaceutically acceptable salt thereof.

14. (Currently amended) A method for treating a disorder of perception, concentration, learning and/or memory, ~~The method of claim 10,~~ where said disorder of perception, concentration, learning and/or memory is a result of Parkinson's disease [[.]] _, comprising administering to a mammal in need of such treatment an effective amount of a

selective PDE 2 inhibitor which inhibits human PDE 2 more strongly than it inhibits the human cAMP PDEs 3B, 4B and 7B, and which has the general formula (I)



(I)

wherein

A=D represents N=N, N=CH or CR^5=N, in which R^5 denotes hydrogen, methyl, ethyl or methoxy,

R^1 and R^2 represent, together with the adjacent carbon atom, hydroxymethylene or carbonyl, and

R^3 and R^4 represent independently of one another methyl, ethyl, methoxy, ethoxy or a radical of the formula $SO_2NR^6R^7$,

in which

R^6 and R^7 denote, independently of one another, hydrogen, C_1-C_6-alkyl, C_3-C_7-cycloalkyl, or

R^6 and R^7 form, together with the adjacent nitrogen atom, an azetidine-1-yl, pyrrol-1-yl, piperid-1-yl, azepin-1-yl, 4-methylpiperazin-1-yl or morpholin-1-yl radical,

or a pharmaceutically acceptable salt thereof.

15. (Cancelled)

16. (Cancelled)